Sichuan Enray Pharmaceutical Technology

Enray Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the discovery and development of next-generation small molecule drugs. The company utilizes a proprietary structure-based drug design (SBDD) platform to address high-value targets in oncology and immunology. Its lead candidate, ER-0040, is a highly selective TYK2 inhibitor currently in Phase 1 clinical trials for the treatment of psoriasis and other autoimmune disorders. Enray's pipeline also includes promising programs targeting HPK1 and SOS1, aimed at overcoming resistance in cancer therapy. Founded by industry veterans with extensive experience at global pharmaceutical firms, the company is backed by prominent venture capital investors. Enray aims to deliver innovative therapies that provide superior efficacy and safety profiles for patients worldwide.